Administration of pantoprazole and its effects on gastric PH,inflammatory & anti inflammatory factors in critically ill patients.

Recruiting

• Conditions: Gastric acidity; Inflamatory & Anti inflamatory cytokines in gastric juice and blood; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon; Inflammatory and Immune System - Other inflammatory or immune system disorders

• Registration Number: ACTRN12611000647932
• Lead Sponsor: Tehran university of medical sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-06-23
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Inclusion Criteria :
1-Age>18
2-Clinical need for a nasogastric tube
3-Expectation of 48 hrs of nothing by mouth” status
4-Baseline gastric pH <3.5
5-High risk patients for stress ulcer(one of these risk
factors)
patients with Coagulopathy disorders.
Ventilator dependant patients, shock, Respiratory failure, trauma

Exclusion Criteria

1-History of peptic ulcer disease
2-Patients with zollinger Ellison
3-Recipients of H2 blockers & NSAIDS
4-Tube feeding
5-Creatinine>2 or Creatinine > %25 increase in base line
6-Abnormal LFT (3 times>base line)
7- Renal failure

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in inflamatory & anti inflamatory cytokines(IL1,TNFa vs IL10,EGF) in gastric juice, ELISA IMMUNOASSAY[0,12,24&48 hours after starting Administration of pantprazole or Ranitidine]

Secondary Outcome Measures

Name	Time	Method
Changes in inflamatory anti inflamatory cytokines(IL1,TNFa vs IL10,EGF) in plasma,ELISA IMMUNOASSAY[0,12,24&48 hours after starting Administration of pantprazole or Ranitidine]